Get started

Financials · WHWK

Whitehawk Therapeutics Inc. (WHWK) financials

For the twelve months ended Jun 30, 2026, Whitehawk Therapeutics Inc. reported $0 of revenue and -$79.83M of net income.

Revenue, TTM
$0
Revenue growth, YoY
-100.0%
Net income, TTM
-$79.83M
Free cash flow, TTM
-$69.35M
Cash
$85.23M
Market cap
$178.4M
Annual revenue$7.14M
FY2018FY2025
Annual net income-$20.60M
FY2016FY2025
Annual free cash flow-$97.98M
FY2016FY2025

WHWK revenue and earnings growth

WHWK revenueQ2 2026$0

FY YoY
-72.5%
5Y CAGR
-12.6%

WHWK revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $7.14M, down 72.5% from fiscal 2024. Compound annual growth was -12.6% over 5 years. It rose in 3 of the last 5 fiscal years.

WHWK net incomeQ2 2026-$16.64M

WHWK net income was -$16.64M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$52.62M a year earlier. For the full fiscal 2025 it was -$20.60M, compared with -$63.69M in fiscal 2024.

WHWK EPSQ2 2026-$0.20

WHWK diluted EPS was -$0.20 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.76 a year earlier. For the full fiscal 2025 it was -$0.33.

WHWK free cash flowQ2 2026-$14.53M

WHWK free cash flow was -$14.53M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$52.96M a year earlier. For the full fiscal 2025 it was -$97.98M, compared with -$61.20M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue$7.14M$25.98M$24.35M$15.22M$14.00M$14.00M$0$20.16M--
Cost of revenue$760.0K$3.02M$2.81M$1.33M$0-----
Gross profit$6.38M$22.96M$21.55M$13.88M$14.00M-----
Research and development$90.96M$51.03M$48.93M$32.66M$19.67M$15.01M$12.82M$17.85M$12.15M$11.37M
Selling, general and admin$29.82M$36.75M$44.55M$40.18M$18.51M$2.12M$9.76M$13.49M$9.24M$5.27M
Operating income-$114.40M-$67.46M-$71.93M-$62.68M-$111.22M-$2.55M-$24.44M-$11.18M-$21.39M-$16.63M
Interest expense$0$154.0K$231.0K$230.0K$665.0K$815.0K---$9.9K
Pre-tax income-$20.60M-$63.69M-$65.77M-$60.51M-$110.09M-$3.48M----
Income tax$0$0$0$0$2.0K$2.0K----
Net income-$20.60M-$63.69M-$65.77M-$60.51M-$110.09M-$3.48M-$23.27M-$10.40M-$21.40M-$16.98M
EPS, basic-$0.33-$2.36-$2.44-$2.69-$12.41-$1.76-$9.55-$5.19-$17.25-$410.71
EPS, diluted-$0.33-$2.36-$2.44-$2.69-$12.41-$1.76-$9.55-$5.19-$17.25-$410.71
Diluted shares61.9M27.0M26.9M22.5M8.9M2.5M2.4M2.0M1.3M50,905.373

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Cash and equivalents$37.57M$28.67M$62.89M$39.02M$148.99M$4.46M$38.52M$62.61M$20.26M$1.61M
Short-term investments$108.13M$18.57M$45.96M$133.54M$0----$50.0K
Receivables$0$5.90M$5.49M$1.86M$0$14.15M---$4.2K
Inventory$0$5.31M$6.43M$1.86M$0-----
Current assets$149.01M$61.29M$124.59M$180.03M$151.27M$18.68M$39.57M$63.98M$20.90M$2.23M
Total assets$150.83M$70.32M$132.42M$184.24M$157.91M$18.82M$39.94M$64.12M$21.03M$2.40M
Current liabilities$14.52M$17.07M$26.39M$18.84M$15.27M$30.06M$3.33M$5.46M$3.59M$14.86M
Long-term debt-----$1.10M----
Total debt-----$1.10M----
Total liabilities$14.52M$17.84M$27.23M$25.86M$21.50M$31.26M$3.40M$5.46M--
Shareholders' equity$136.31M$52.48M$105.19M$158.38M$136.41M-$12.43M-$9.09M$58.67M$17.44M-$86.22M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Operating cash flow-$97.43M-$59.55M-$59.66M-$49.64M-$22.42M-$12.70M-$23.85M-$5.81M-$18.88M-$15.72M
Capital expenditures$552.0K$1.65M$3.97M$444.0K$46.0K$19.0K$237.0K$37.9K$8.9K$113.3K
Free cash flow-$97.98M-$61.20M-$63.63M-$50.08M-$22.47M-$12.72M-$24.09M-$5.85M-$18.89M-$15.83M
Investing cash flow$11.89M$25.20M$83.21M-$132.89M$25.15M-$19.0K-$237.0K-$37.9K$41.1K-$113.3K
Financing cash flow$94.38M$130.0K$326.0K$72.62M$141.80M$1.19M-$48.20M$37.50M$12.30M
Dividends paid---$0$4.41M-----
Stock-based compensation$9.87M$10.84M$11.95M$9.64M$2.11M$139.0K$1.09M$3.43M$649.4K$488.3K
Depreciation and amortization$79.0K$193.0K$169.0K$159.0K$105.0K$9.0K----

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
FY2017
Dec 31, 2017
FY2016
Dec 31, 2016
Revenue growth, YoY-72.5%6.7%60.1%8.7%0.0%--100.0%---
Gross margin89.4%88.4%88.5%91.2%100.0%-----
Operating margin-1601.1%-259.6%-295.4%-411.9%-794.4%-18.2%--55.5%--
Net margin-288.3%-245.1%-270.0%-397.7%-786.4%-24.8%--51.6%--
Free cash flow margin-1371.4%-235.6%-261.3%-329.2%-160.5%-90.9%--29.0%--
Return on equity-15.1%-121.4%-62.5%-38.2%-80.7%---17.7%-122.7%-
Return on assets-13.7%-90.6%-49.7%-32.8%-69.7%-18.5%-58.3%-16.2%-101.8%-708.6%
Current ratio10.263.594.729.569.900.6211.8711.735.820.15

Source: XBRL data Whitehawk Therapeutics Inc. files with the SEC, latest filing dated Aug 6, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 4-for-67, first reported Mar 17, 2022.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

WHWK peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
WHWK$0-100.0%-$79.83M-$178.4M
LLY$86.46B+45.5%$27.58B31.9%$1.27T
JNJ$99.33B+7.8%$16.09B16.2%$664.95B
ABBV$66.01B+10.7%$10.34B15.7%$514.92B
MRK$67.38B+4.9%$2.45B3.6%$361.71B
NVS$54.53B+8.4%$13.98B25.6%$310.17B
AZN$58.74B+8.6%$10.22B17.4%$289.10B
ABT$48.23B+10.0%$4.70B9.7%$190.39B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$178.51B

WHWK FAQ

7 questions
  • What is WHWK revenue?
    Whitehawk Therapeutics Inc. (WHWK) reported $0 of revenue for the twelve months ended Jun 30, 2026. That is down 100.0% from the year before. Revenue for fiscal 2025 was $7.14M.
  • Is WHWK profitable?
    No. Whitehawk Therapeutics Inc. reported a net loss of $79.83M for the twelve months ended Jun 30, 2026.
  • How much cash and debt does WHWK have?
    Whitehawk Therapeutics Inc. reported $85.23M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is WHWK revenue growing?
    Whitehawk Therapeutics Inc.'s revenue changed -72.5% in fiscal 2025, to $7.14M. Its compound annual growth rate was -12.6% over 5 years.
  • What is WHWK free cash flow?
    Whitehawk Therapeutics Inc. generated -$69.35M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$69.35M less capital expenditures.
  • When did WHWK last report financial results?
    The latest statements here come from Whitehawk Therapeutics Inc.'s 10-Q filed on Aug 6, 2026, covering the period ended Jun 30, 2026.
  • Where does this WHWK financial data come from?
    Quantisnow builds these statements from the structured XBRL data Whitehawk Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.